RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.
Wiegmans, Adrian P
RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. [electronic resource] - Oncotarget 09 2016 - 60087-60100 p. digital
Publication Type: Journal Article
1949-2553
10.18632/oncotarget.11065 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Cell Line, Tumor
Cell Proliferation--drug effects
Cell Survival--drug effects
Humans
Imidazoles--administration & dosage
Mice, Inbred BALB C
Mice, Nude
Mitogen-Activated Protein Kinase 14--antagonists & inhibitors
Poly (ADP-Ribose) Polymerase-1--antagonists & inhibitors
Pyridines--administration & dosage
Quinazolinones--administration & dosage
Rad51 Recombinase--antagonists & inhibitors
Signal Transduction
Triple Negative Breast Neoplasms--drug therapy
Xenograft Model Antitumor Assays--methods
RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy. [electronic resource] - Oncotarget 09 2016 - 60087-60100 p. digital
Publication Type: Journal Article
1949-2553
10.18632/oncotarget.11065 doi
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Cell Line, Tumor
Cell Proliferation--drug effects
Cell Survival--drug effects
Humans
Imidazoles--administration & dosage
Mice, Inbred BALB C
Mice, Nude
Mitogen-Activated Protein Kinase 14--antagonists & inhibitors
Poly (ADP-Ribose) Polymerase-1--antagonists & inhibitors
Pyridines--administration & dosage
Quinazolinones--administration & dosage
Rad51 Recombinase--antagonists & inhibitors
Signal Transduction
Triple Negative Breast Neoplasms--drug therapy
Xenograft Model Antitumor Assays--methods